P
Paula Marlton
Researcher at University of Queensland
Publications - 156
Citations - 5771
Paula Marlton is an academic researcher from University of Queensland. The author has contributed to research in topics: Myeloid leukemia & Internal medicine. The author has an hindex of 30, co-authored 144 publications receiving 4877 citations. Previous affiliations of Paula Marlton include Royal Brisbane and Women's Hospital & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia.
Pu Liu,Susan A. Tarlé,Amitav Hajra,David F. Claxton,Paula Marlton,Matthew L. Freedman,Michael J. Siciliano,Francis S. Collins +7 more
TL;DR: In six of six inv(16) patient samples tested, an in-frame fusion messenger RNA was demonstrated that connected the first 165 amino acids of CBF beta with the tail region of SMMHC, which may result in dimerization of the CBFbeta fusion protein, which in turn would lead to alterations in transcriptional regulation and contribute to leukemic transformation.
Journal ArticleDOI
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Linda Holmfeldt,Lei Wei,Ernesto Diaz-Flores,Michael Walsh,Jinghui Zhang,Li Ding,Debbie Payne-Turner,Michelle L. Churchman,Anna Andersson,Shann Ching Chen,Kelly McCastlain,Jared Becksfort,Jing Ma,Gang Wu,Samir Patel,Susan L. Heatley,Letha A. Phillips,Guangchun Song,John Easton,Matthew Parker,Xiang Chen,Michael Rusch,Kristy Boggs,Bhavin Vadodaria,Erin Hedlund,Christina D. Drenberg,Sharyn D. Baker,Deqing Pei,Cheng Cheng,Robert Huether,Charles Lu,Robert S. Fulton,Lucinda Fulton,Yashodhan Tabib,David J. Dooling,Kerri Ochoa,Mark D. Minden,Ian D. Lewis,L. Bik To,Paula Marlton,Andrew W. Roberts,Gordana Raca,Wendy Stock,Geoffrey Neale,Hans G. Drexler,Ross A. Dickins,David W. Ellison,Sheila A. Shurtleff,Ching-Hon Pui,Raul C. Ribeiro,Meenakshi Devidas,Andrew J. Carroll,Nyla A. Heerema,Brent L. Wood,Michael J. Borowitz,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Susana C. Raimondi,Elaine R. Mardis,Richard K. Wilson,James R. Downing,Stephen P. Hunger,Mignon L. Loh,Charles G. Mullighan +63 more
TL;DR: Both near-haploid and low-hypodiploid leukemic cells show activation of Ras-signaling and phosphoinositide 3-kinase (PI3K)-signaling pathways and are sensitive to PI3K inhibitors, indicating that these drugs should be explored as a new therapeutic strategy for this aggressive form of leukemia.
Journal ArticleDOI
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Kirsten Fischer,Jasmin Bahlo,Anna-Maria Fink,Valentin Goede,Carmen D. Herling,Paula Cramer,Petra Langerbeins,Julia von Tresckow,Anja Engelke,Christian Maurer,Gabor Kovacs,Marco Herling,Eugen Tausch,Karl Anton Kreuzer,Barbara Eichhorst,Sebastian Böttcher,John F. Seymour,Paolo Ghia,Paula Marlton,Paula Marlton,Michael Kneba,Clemens M. Wendtner,Hartmut Döhner,Stephan Stilgenbauer,Michael Hallek +24 more
TL;DR: First-line chemoimmunotherapy with FCR induces long-term remissions and highly relevant improvement in OS in specific genetic subgroups of fit patients with CLL, in particular those with IGHV MUT.
Journal ArticleDOI
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Constantine S. Tam,Stephen Opat,Shirley D'Sa,Wojciech Jurczak,Hui Peng Lee,Gavin Cull,Gavin Cull,Roger G. Owen,Paula Marlton,Paula Marlton,Björn E. Wahlin,Ramón García Sanz,Helen McCarthy,Stephen P. Mulligan,Alessandra Tedeschi,Jorge J. Castillo,Jarosław Czyż,Carlos Fernández de Larrea,David Belada,Edward N. Libby,Jeffrey Matous,Marina Motta,Tanya Siddiqi,Monica Tani,Marek Trneny,Monique C. Minnema,Christian Buske,Veronique Leblond,Judith Trotman,Judith Trotman,Wai Y. Chan,Jingjing Schneider,Sunhee Ro,Aileen Cohen,Jane Huang,Meletios A. Dimopoulos +35 more
TL;DR: Zanubrutinib treatment was associated with a trend toward better response quality and less toxicity, particularly cardiovascular toxicity, which demonstrate that zanubRutinIB and ibrut inib are highly effective in the treatment of WM.
Journal ArticleDOI
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.
Maher K. Gandhi,Eleanore Lambley,Eleanore Lambley,Eleanore Lambley,Jaikumar Duraiswamy,Jaikumar Duraiswamy,Jaikumar Duraiswamy,Ujjwal Dua,Ujjwal Dua,Ujjwal Dua,Corey Smith,Corey Smith,Corey Smith,Suzanne L. Elliott,Suzanne L. Elliott,Suzanne L. Elliott,Devinder Gill,Devinder Gill,Devinder Gill,Paula Marlton,Paula Marlton,Paula Marlton,John F. Seymour,John F. Seymour,John F. Seymour,Rajiv Khanna,Rajiv Khanna,Rajiv Khanna +27 more
TL;DR: It is shown that a marker of regulatory T cells, LAG-3, is strongly expressed on infiltrating lymphocytes present in proximity to HRS cells, which indicates a pivotal role for regulatory T Cells and LAG3 in the suppression of EBV-specific cell-mediated immunity in HL.